Imatinib trough levels: A potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

被引：0
|
作者：
Natarajan, H. [1 ]
Kumar, L. [2 ]
Bakhshi, S. [2 ]
Sharma, A. [2 ]
Velpandian, T. [1 ]
Gogia, A. [2 ]
Gupta, Y. K. [1 ]
机构：
[1] All India Inst Med Sci, Clin Pharmacol, New Delhi, India
[2] All India Inst Med Sci, Med Oncol, New Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335O
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
    Angelini, Sabrina
    Soverini, Simona
    Ravegnini, Gloria
    Barnett, Matt
    Turrini, Eleonora
    Thornquist, Mark
    Pane, Fabrizio
    Hughes, Timothy P.
    White, Deborah L.
    Radich, Jerald
    Kim, Dong Wook
    Saglio, Giuseppe
    Cilloni, Daniela
    Iacobucci, Ilaria
    Perini, Giovanni
    Woodman, Richard
    Cantelli-Forti, Giorgio
    Baccarani, Michele
    Hrelia, Patrizia
    Martinelli, Giovanni
    HAEMATOLOGICA, 2013, 98 (02) : 193 - 200
  • [42] Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib
    Latagliata, Roberto
    Volpicelli, Paola
    Breccia, Massimo
    Vozella, Federico
    Romano, Angela
    Montagna, Chiara
    Molica, Matteo
    Finsinger, Paola
    Carmosino, Ida
    Serrao, Alessandra
    Zacheo, Irene
    Santopietro, Michelina
    Salaroli, Adriano
    Alimena, Giuliana
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 105 - 108
  • [43] Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
    Forrest, Donna L.
    Trainor, Shannon
    Brinkman, Ryan R.
    Barnett, Michael J.
    Hogge, Donna E.
    Nevill, Thomas J.
    Shepherd, John D.
    Nantel, Stephen H.
    Toze, Cynthia L.
    Sutherland, Heather J.
    Song, Kevin W.
    Lavoie, Julye C.
    Power, Maryse M.
    Abou-Mourad, Yasser
    Smith, Clayton A.
    LEUKEMIA RESEARCH, 2009, 33 (02) : 271 - 275
  • [44] COMPLETE MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB THERAPY
    Aksenova, E.
    Chelysheva, E.
    Krutov, A.
    Soldatova, I.
    Misiurin, A.
    Vinogradova, O.
    Gusarova, G.
    Zakharova, E.
    Sokolova, M.
    Nemchenko, I.
    Kuznetsov, S.
    Lazareva, O.
    Vorontsova, A.
    Kolosheinova, T.
    Kolosova, L.
    Goryacheva, S.
    Ivanova, T.
    Turkina, A.
    Khoroshko, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 346 - 346
  • [45] MULTICENTER EXPERIENCE WITH IMATINIB MESYLATE IN 202 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Carella, A. M.
    Orlandi, E.
    Lazzarino, M.
    Annunziata, M.
    Ferrara, F.
    Pungolino, E.
    Morra, E.
    Barate, C.
    Petrini, M.
    Miglino, M.
    Gobbi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 222
  • [46] ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
    Ernst, Thomas
    Schoenfeld, Lioba
    Rinke, Jenny
    Hinze, Anna
    Nagel, Saskia N.
    Schaefer, Vivien
    Schenk, Thomas
    Fabisch, Christian
    Bruemmendorf, Tim H.
    Burchert, Andreas
    le Coutre, Philipp
    Krause, Stefan W.
    Saussele, Susanne
    Safizadeh, Fatemeh
    Pfirrmann, Markus
    Hochhaus, Andreas
    BLOOD, 2022, 140
  • [47] Multicenter experience with imatinib mesylate in 202 newly diagnosed chronic myeloid leukemia (CML) patients
    Carella, M.
    Orlandi, E.
    Lazzarino, M.
    Annunziata, M.
    Ferrara, F.
    Pungolino, E.
    Morra, E.
    Barate, C.
    Petrini, M.
    Miglino, M.
    Gobbi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients
    Soverini, S.
    Angelini, S.
    Barnett, M.
    Thornquist, M.
    Turrini, E.
    Rosti, G.
    Hrelia, P.
    Kalebic, T.
    Baccarani, M.
    Martinelli, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Rosti, G
    Trabacchi, E
    Bassi, S
    Bonifazi, F
    De Vivo, A
    Martinelli, G
    Alberti, D
    Fincato, G
    Saglio, G
    Baccarani, M
    HAEMATOLOGICA, 2003, 88 (03) : 256 - 259
  • [50] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Cortes, Jorge
    Shah, Sandip
    Ayala, Manuel
    Moiraghi, Beatriz
    Shen, Zhixiang
    Mayer, Jiri
    Pasquini, Ricardo
    Nakamae, Hirohisa
    Huguet, Francoise
    Boque, Concepcion
    Chuah, Charles
    Bleickardt, Eric
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Szatrowski, Ted
    Shapiro, David
    Baccarani, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
12345